Immunocore (NASDAQ:IMCR – Get Free Report) and Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Immunocore and Bicycle Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunocore | 2 | 3 | 6 | 1 | 2.50 |
| Bicycle Therapeutics | 1 | 4 | 5 | 0 | 2.40 |
Immunocore currently has a consensus target price of $52.86, suggesting a potential upside of 90.07%. Bicycle Therapeutics has a consensus target price of $13.57, suggesting a potential upside of 324.11%. Given Bicycle Therapeutics’ higher probable upside, analysts clearly believe Bicycle Therapeutics is more favorable than Immunocore.
Earnings & Valuation
This table compares Immunocore and Bicycle Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunocore | $400.02 million | 3.58 | -$35.51 million | ($0.65) | -42.78 |
| Bicycle Therapeutics | $72.86 million | 3.08 | -$218.96 million | ($2.03) | -1.58 |
Immunocore has higher revenue and earnings than Bicycle Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Immunocore has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.
Insider & Institutional Ownership
84.5% of Immunocore shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Immunocore and Bicycle Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunocore | -7.48% | -7.96% | -2.93% |
| Bicycle Therapeutics | -169.75% | -26.02% | -22.30% |
Summary
Immunocore beats Bicycle Therapeutics on 10 of the 15 factors compared between the two stocks.
About Immunocore
Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
